NO942834D0 - 1-Benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, preparation thereof, and pharmaceutical compositions containing them - Google Patents

1-Benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, preparation thereof, and pharmaceutical compositions containing them

Info

Publication number
NO942834D0
NO942834D0 NO942834A NO942834A NO942834D0 NO 942834 D0 NO942834 D0 NO 942834D0 NO 942834 A NO942834 A NO 942834A NO 942834 A NO942834 A NO 942834A NO 942834 D0 NO942834 D0 NO 942834D0
Authority
NO
Norway
Prior art keywords
benzenesulfonyl
indol
dihydro
derivatives
preparation
Prior art date
Application number
NO942834A
Other languages
Norwegian (no)
Other versions
NO301824B1 (en
NO942834L (en
Inventor
Alain Di Malta
Loic Foulon
Georges Garcia
Dino Nisato
Richard Roux
Claudine Serradeil-Legal
Gerard Valette
Jean Wagnon
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of NO942834D0 publication Critical patent/NO942834D0/en
Publication of NO942834L publication Critical patent/NO942834L/en
Publication of NO301824B1 publication Critical patent/NO301824B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/90—Benzo [c, d] indoles; Hydrogenated benzo [c, d] indoles
    • C07D209/92—Naphthostyrils
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
NO942834A 1993-07-30 1994-07-29 1-Benzenesulfonyl-1,3-dihydro-indol-2-one derivatives and pharmaceutical compositions containing them NO301824B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9309404A FR2708605A1 (en) 1993-07-30 1993-07-30 N-sulfonylindol-2-one derivatives, their preparation, pharmaceutical compositions containing them.

Publications (3)

Publication Number Publication Date
NO942834D0 true NO942834D0 (en) 1994-07-29
NO942834L NO942834L (en) 1995-01-31
NO301824B1 NO301824B1 (en) 1997-12-15

Family

ID=9449794

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942834A NO301824B1 (en) 1993-07-30 1994-07-29 1-Benzenesulfonyl-1,3-dihydro-indol-2-one derivatives and pharmaceutical compositions containing them

Country Status (14)

Country Link
EP (1) EP0636608A1 (en)
JP (1) JPH07247269A (en)
KR (1) KR950003271A (en)
CN (1) CN1107467A (en)
CA (1) CA2129215A1 (en)
FI (1) FI943570A (en)
FR (1) FR2708605A1 (en)
HU (1) HUT70408A (en)
IL (1) IL110482A (en)
NO (1) NO301824B1 (en)
NZ (1) NZ264122A (en)
RU (1) RU2141476C1 (en)
TW (1) TW375609B (en)
ZA (1) ZA945656B (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2740136B1 (en) * 1995-10-24 1998-01-09 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5756497A (en) * 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
FR2757157B1 (en) * 1996-12-13 1999-12-31 Sanofi Sa INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
NZ505280A (en) 1997-11-20 2003-01-31 Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment of diseases characterised by abnormal cell proliferation
CA2310750A1 (en) * 1997-11-20 1999-06-03 President And Fellows Of Harvard College Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6291449B1 (en) 1998-09-23 2001-09-18 Children's Medical Center Corporation Use of 11-phenyl-dibenzazepine compounds to treat diarrhea or scours
US6800658B2 (en) 1997-11-20 2004-10-05 Children's Medical Center Corporation Substituted diphenyl indanone, indane and indole compounds and analogues thereof useful for the treatment of prevention of diseases characterized by abnormal cell proliferation
US6992079B2 (en) 1997-11-20 2006-01-31 President Fellows of Harvard College Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation
US6268359B1 (en) 1998-01-28 2001-07-31 Senju Pharmaceutical Co., Ltd. Preventives or remedies for vision disorders
US6069153A (en) * 1998-05-12 2000-05-30 American Home Products Corporation Indenoindoles and benzocarbazoles as estrogenic agents
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
WO1999065525A1 (en) * 1998-06-19 1999-12-23 Wakamoto Pharmaceutical Co., Ltd. Ocular tension lowering agents and phosphoric ester derivatives
US6159959A (en) * 1999-05-06 2000-12-12 American Home Products Corporation Combined estrogen and antiestrogen therapy
FR2807038B1 (en) * 2000-04-03 2002-08-16 Sanofi Synthelabo NOVEL INDOLIN-2-ONE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6673790B1 (en) 2000-04-03 2004-01-06 Sanofi-Synthelabo Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
NZ523450A (en) * 2000-07-05 2004-11-26 Ortho Mcneil Pharm Inc Nonpeptide substituted spirobenzoazepines as vasopressin receptor antagonists
JP2004529110A (en) 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ Indole derivatives with vascular damage activity
DE10222034A1 (en) * 2002-05-17 2003-11-27 Bayer Ag New 2-benzenesulfonyl-3,4-dihydro-2(1H)-isoquinoline derivatives, are PPAR-delta activators useful e.g. for treating coronary heart disease, dyslipidemia or restenosis
DE10229777A1 (en) * 2002-07-03 2004-01-29 Bayer Ag Indoline-phenylsulfonamide derivatives
DE10300099A1 (en) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Indole-phenylsulfonamide derivatives
EA011089B1 (en) 2003-06-17 2008-12-30 Янссен Фармацевтика Н.В. Substituted spirobenzazepines
DE10335449A1 (en) * 2003-08-02 2005-02-17 Bayer Healthcare Ag New 2-((indoline-1-sulfonyl)-tetralinyl or indanyl)-alkanoic acid derivatives, are PPAR-delta activators useful e.g. for treating or preventing stroke, arteriosclerosis, coronary heart disease or dyslipidemia
US7414052B2 (en) 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
US7517899B2 (en) 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
BRPI0510260A (en) 2004-04-27 2007-10-23 Wyeth Corp method for purifying a compound and pharmaceutical kit
FR2875499B1 (en) * 2004-09-20 2006-10-27 Sanofi Aventis Sa NOVEL INDOLIN-2-ONE PYRIDINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
AU2005316739A1 (en) 2004-12-13 2006-06-22 Galileo Pharmaceuticals, Inc. Spiro derivatives as lipoxygenase inhibitors
CA2593044A1 (en) * 2004-12-31 2006-07-13 Abbott Gmbh & Co. Kg Substituted oxindole derivatives, medicaments containing said derivatives and use thereof
DE102005014936A1 (en) * 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg New substituted oxindole derivatives are vasopressin receptor binders useful to treat e.g. diabetes insipidus, enuresis nocturna, incontinence, hypertonia, heart failure, myocardial infarction, coronary spasm and renal disorders
AR053710A1 (en) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc SPIROHETEROCICLIC COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS
AR056968A1 (en) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc ESPIRO-OXINDOL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
TWI315304B (en) * 2006-08-31 2009-10-01 Univ Taipei Medical Indoline-sulfonamides compounds
EP2076517A1 (en) 2006-09-22 2009-07-08 Janssen Pharmaceutica N.V. Spiro benzazepines as vasopressin antagonists
CA2665849A1 (en) 2006-09-22 2008-03-27 Janssen Pharmaceutica N.V. Spiro benzazepines used as vasopressin antagonists
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
FR2930249B1 (en) * 2008-04-21 2010-05-14 Sanofi Aventis NOVEL 3-AMINOALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
ES2527589T3 (en) 2008-04-24 2015-01-27 Msd K.K. Long chain fatty acid elongation enzyme inhibitor comprising an arylsulfonyl derivative as active ingredient
CN102256983B (en) 2008-10-17 2017-04-05 泽农医药公司 Spiral shell oxindole compounds and its purposes as therapeutic agent
US8101647B2 (en) 2008-10-17 2012-01-24 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
EP2246326A1 (en) 2009-05-02 2010-11-03 Bayer CropScience AG Method for producing oxindoles and ortho-substituted anilines and their use as intermediate products for syntheses
AR077252A1 (en) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc ESPIROOXINDOL COMPOUND ENANTIOMERS AND THEIR USES AS THERAPEUTIC AGENTS
CN102753556B (en) 2009-10-14 2015-05-13 泽农医药公司 Synthetic methods for spiro-oxindole compounds
BR112012021086A2 (en) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
WO2011141364A1 (en) * 2010-05-10 2011-11-17 Bayer Cropscience Ag Process for preparing substituted 1,3-dihydro-2h-indol-2-ones
WO2012028162A1 (en) 2010-09-01 2012-03-08 Bayer Cropscience Ag Process for preparing oxindoles and ortho-substituted anilines and the use thereof as intermediates for syntheses
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
CN114213396B (en) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 Indole-2-ketone compound and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803217A (en) * 1986-12-24 1989-02-07 Merck & Co., Inc. Hapalindolinone compounds as vassopressin antagonists
CA2037287A1 (en) * 1990-03-02 1991-09-03 Ben E. Evans Spirocyclic oxytocin antagonists
FR2686878B1 (en) * 1992-01-30 1995-06-30 Sanofi Elf DERIVATIVES OF N-SULFONYL OXO-2 INDOLE, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.

Also Published As

Publication number Publication date
FI943570A0 (en) 1994-07-29
AU6878994A (en) 1995-02-09
AU684791B2 (en) 1998-01-08
KR950003271A (en) 1995-02-16
CA2129215A1 (en) 1995-01-31
CN1107467A (en) 1995-08-30
HU9402232D0 (en) 1994-09-28
NZ264122A (en) 1996-07-26
EP0636608A1 (en) 1995-02-01
JPH07247269A (en) 1995-09-26
IL110482A (en) 1999-04-11
FI943570A (en) 1995-01-31
ZA945656B (en) 1995-03-09
RU2141476C1 (en) 1999-11-20
TW375609B (en) 1999-12-01
IL110482A0 (en) 1994-10-21
FR2708605A1 (en) 1995-02-10
NO301824B1 (en) 1997-12-15
RU94027576A (en) 1996-05-27
HUT70408A (en) 1995-10-30
NO942834L (en) 1995-01-31

Similar Documents

Publication Publication Date Title
NO942834D0 (en) 1-Benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, preparation thereof, and pharmaceutical compositions containing them
NO942835D0 (en) 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives, their preparation and pharmaceutical compositions containing them
IL111314A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL109234A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
ZA9811759B (en) Novel indole derivatives, processes for their preparation, their use and pharmaceutical compositions containing them.
NO20001409D0 (en) Carboxamidothiazole derivatives, processes for their preparation and pharmaceutical compositions
IL105412A0 (en) Indole derivatives,their preparation and pharmaceutical compositions containing them
FI942913A0 (en) Isatin derivatives, methods for their preparation and pharmaceutical compositions containing them
IL108729A0 (en) Pyrrolo-pyridine derivatives, their preparation and pharmaceutical compositions containing them
IL108859A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
HUT74464A (en) 1n-alkyl-n-arylpyrimidinamines and derivatives thereof, and pharmaceutical compositions containing them
NO976128L (en) Compounds and pharmaceutical compositions containing them
DK1112266T3 (en) Substituted 4-amino-2-arylpyrimidines, their preparation and use, and pharmaceutical compositions containing them
NO305075B1 (en) Glycinamide derivatives, pharmaceutical surfactants containing them and intermediates for their preparation
IL111294A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL110980A0 (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
IL109703A0 (en) Substituted carbazole derivatives, processes for their preparation and pharmaceutical compositions containing them
IL112097A0 (en) Indoline derivatives, their preparation and pharmaceutical compositions containing them
DK1095020T3 (en) 2-Aminopyridine derivatives, their use as pharmaceuticals and pharmaceutical compositions containing them
NO950537L (en) Polysubstituted 3-acylamino-5-phenyl-1,4-benzodiazepin-2-one derivatives, processes for their preparation, and pharmaceutical compositions containing them
HUP9801386A3 (en) Indazolecarboxamide derivatives, preparation thereof and pharmaceutical compositions containing them
HUP0001940A3 (en) Benzisothiazole derivatives, their use and pharmaceutical compositions containing them
NO306114B1 (en) Substituted 4-phenylthiazole derivatives and pharmaceutical compositions containing them
NO960272L (en) Oxathiolanes, processes for their preparation and pharmaceutical compositions containing the same
NO923720D0 (en) TIENOCYCLOPENTANONOXIMERS, PREPARING THEREOF AND PHARMACEUTICAL MIXTURES CONTAINING THEM

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN JANUARY 2001